Effects of antihypertensive drugs on central blood pressure: new evidence, more challenges
Por: Giacomo Pucci, Francesca Battista y Giuseppe Schillaci. Hypertension Research (2014) 37, 10–12.
βa-blocking drugs have long been used as a first-line therapy for hypertension because of their well-established efficacy in lowering brachial blood pressure (BP) and their long-term favorable effects on all-cause and cardiovascular mortality, as shown in a number of prospective large-scale trials and meta-analyses. More recently, their use as a preferred strategy for the treatment of essential hypertension has been challenged, as their protective effect on incident stroke may be suboptimal.
Estudios importantes sobre hipertension arterial de Cuba y el mundo.
Apparent and true resistant hypertension: definition, prevalence and outcomes
Por: E Judd y D A Calhoun. Journal of Human Hypertension 16 January 2014; doi: 10.1038/jhh.
Resistant hypertension, defined as blood pressure (BP) remaining above goal despite the use of greater than or equal to3 antihypertensive medications at maximally tolerated doses (one ideally being a diuretic) or BP that requires greater than or equal to4 agents to achieve control, has received more attention with increased efforts to improve BP control rates and the emergence of device-based therapies for hypertension. This classically defined resistant group consists of patients with true resistant hypertension, controlled resistant hypertension and pseudo-resistant hypertension.
Por: Giuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, Giustino Parruti, Giacomo Pucci, Antonio Di Biagio, Leonardo Calza, Giancarlo Orofino, Laura Carenzi, Enisia Cecchini, Giordano Madeddu, Tiziana Quirino, Giuseppe Schillaci for the CISAI study group. American Journal of Hypertension, Volume 27 Issue 2, Pp. 222-228, February 2014.
We aimed to assess the prevalence of hypertension in an unselected human immunodeficiency virus (HIV)–infected population and to identify factors associated with hypertension prevalence, treatment, and control. Atherosclerotic cardiovascular disease (CVD), a leading cause of morbidity and mortality in the general population, is an increasing concern for human immunodeficiency virus (HIV)–infected patients. HIV-infected individuals are exposed to accelerated vascular aging,1 and this issue has become even more relevant since antiretroviral therapy has impressively extended the life span of HIV-infected individuals.
Sex and Age Differences in the Relation of Depressive Symptoms With Blood Pressure
Por: Mauli T. Shah, Alan B. Zonderman y Shari R. Waldstein. American Journal of Hypertension, Volume 26, Issue 12, Pp. 1413-1420.
Longitudinal associations between depressive symptoms and blood pressure have been inconsistent. Most studies have examined incident hypertension as an outcome, and few have examined effect modification.
Depression and depressive symptoms are established risk factors for cardiovascular disease (CVD),1 but the mechanisms underlying this relation are unclear. Hypertension may be a mechanism through which depressive symptoms influence CVD pathogenesis. Prior literature has identified inconsistent longitudinal associations between depressive symptoms and blood pressure (BP).
Results demonstrate sex and age differences in the relation between depressive symptoms and blood pressure. Findings suggest the potential importance of preventing, detecting, and lowering depressive symptoms to prevent hypertension among women and older adults.
Por: F D Fuchs y S C Fuchs. Journal of Human Hypertension (2014) 28, 80–84. ( 8 January 2014).
The risk that lowering blood pressure (BP) excessively increases the incidence of cardiovascular disease—the J-shaped phenomenon—has been a matter of concern endorsed by many experts, particularly in patients with coronary heart disease and diabetes. The results of the Action to Control Cardiovascular Risk in Type 2 Diabetes (ACCORD) trial strengthened the idea that it may be futile to lower BP more intensively in patients with diabetes. Nevertheless, there seems to be no direct J-shaped relation between BP-lowering treatment and outcome.
Comentarios recientes